Thus, CD26 resulted in being more specific than other previously identified stem cell markers, such as IL1-RAP, CD25, and CD90, and emerged as a potential biomarker for the characterization and quantification of CML LSCs. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.